Novartis appoints Sloan Simpson as Global Head of Investor Relations
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Novartis 2023 Financial Results
Novartis announces the company’s fourth quarter and 2023 full year financial results.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.
Violence against innocent people runs counter to our work to improve human health
Novartis condemns all acts of terrorism and violence. Our thoughts are with all those affected by the tragic events that continue to unfold in Israel, Gaza and the West Bank.
Novartis provides support for Moroccan earthquake victims
Novartis is deeply concerned and saddened by the devastation caused by the earthquake in Morocco on September 9, 2023.
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.